Embodiments disclosed herein are directed to an anti-microbial coated urethral plug to reduce catheter associated urinary tract infections (“CAUTI”). A urethral plug is configured to engage a urinary catheter and includes a plug body defining a frustum shape, a lumen configured to receive the urinary catheter, and a slit extending longitudinally and extending from the lumen to a side surface of the plug body. The plug can further include one of a textured surface and a coating disposed on an outer surface and configured to mitigate microbial adhesion. A distal portion of the plug is configured to fit within a urethral opening to create a seal between the side surface of the plug body and the urethral opening. The urethral plug includes coatings, textured surfaces, or the like, and provides protection against the extra-luminal migration of microbes that may cause CAUTI.

The present disclosure relates to methods for embedding drug molecules into medical catheters, tubes, and other medical devices. The catheter, tube, or other medical device is capable of releasing drugs for extended periods of time. Drugs can be loaded into the wall thereof through diffusion from a solution, e.g., loading solution. A counterintuitive approach of using undissolved drug particulates in the solution is employed in some embodiments. The drug in the wall of the device and in the solution (which when stored may be referred to as a storage solution) can be in dynamic equilibrium, yielding stable and easy-to-manufacture products. Heat can be used to significantly speed up the drug loading.

An intrauterine balloon catheter for inhibiting formation of intrauterine adhesions in a mammalian uterus comprising balloon and a sheath, wherein the balloon is at least partially attached to the inner surface of the sheath and wherein the balloon and sheath, when the balloon is inflated, conform to the size and shape of the uterus and contact the wall of the uterus. The catheter further comprises a pressure control lock, clipping unit and one or more therapeutic agents which are therapeutically effective in inhibiting intrauterine adhesion formation.

Compositions and methods for inhibiting and interrupting biofilm formation, and for destabilizing established biofilms are provided, the novel compositions including polymeric resins and monomeric non-polymerizable and polymerizable resins. More particularly, the compositions and methods enable the protection and removal of biofilms from surfaces in the context of medical, consumer, domestic, food service, environmental and industrial applications, where the effects constitute beneficial and desirable biofilm attenuating activity.

Antibacterial coatings and methods of making the antibacterial coatings are described herein. A first branched polyethylenimine (BPEI) layer is formed and a first glyoxal layer is formed on a surface of the BPEI layer. The first BPEI layer and the first glyoxal layer are cured to form a crosslinked BPEI coating. The first BPEI layer can be modified with superhydrophobic moieties, superhydrophilic moieties, or negatively charged moieties to increase the antifouling characteristics of the coating. The first BPEI layer can be modified with contact-killing bactericidal moieties to increase the bactericidal characteristics of the coating.

A protective sleeve for a urinary catheter includes a sleeve configured to extend over an outer surface of the urinary catheter shaft from a proximal insertion end of the catheter shaft to a distal end of the catheter shaft. The protective sleeve includes a protective sleeve tip defining the proximal end portion of the sleeve. The sleeve and the protective sleeve tip are of a single unitary construction and the sleeve and protective sleeve tip are formed of the same thin, flexible film. The protective sleeve tips has a first pre-use configuration when a proximal insertion end of the catheter is not within the protective sleeve tip wherein the protective sleeve tip is in a collapsed state, and a second configuration when a proximal insertion end of a urinary catheter is inserted into the protective sleeve tip, in the second configuration the protective sleeve tip being in an extended state that is configured to cover the proximal insertion end of the urinary catheter shaft and the thin, flexible film conforms to and is supported by the proximal insertion end of the urinary catheter for insertion of the protective sleeve tip into the urethral opening.

Medical products including hydrophilic coating containing silver antimicrobial, hydration medium and a stabilizing agent.

A coated urinary catheter or urinary stent device includes a urinary catheter or stent which, in a deployed position, includes or defines a protective surface area and a protected surface area and a coating upon at least a portion of the protective surface area. The coating includes a lubricant and an antimicrobial and/or pH buffering material. The device is configured such that, upon application of negative pressure to the catheter or stent, tissue of a urinary tract of a patient conforms or collapses onto the protective surface area and is thereby prevented or inhibited from occluding one or more protected drainage holes, ports or perforations of the catheter or stent.

The disclosure provides a method for preventing infection and microbial ingress in medical device connections between tubing sets and medical devices. The tubing set includes a male connector with a distal tip and a recess at the distal tip configured to trap bacterial, and deliver and confine antimicrobial into solution within a cavity formed by the recess. The surface of the recess includes an antimicrobial composition. In certain implementations a male luer comprises a tapered sealing member further comprising a recess containing chlorhexidine acetate.

A method of treating a subject which may be a human suffering from epilepsy which may be a form of epilepsy resistant to treatment and particular patients which are resistant to treatment with oral medication. The method involves positioning a catheter device in the subject's brain and infusing a liquid formulation of a drug into a portion of the subject's brain through an infusion lumen at a rate of 5, 4, 3, 2, or 1 ml or less per day ±50%. The infusion may be constant and corrected by aspirating fluid from the patient's brain and testing the aspirated fluid for drug concentration. The rate of infusion by the formulation and the concentration of drug may be adjusted based on patient responsiveness.